Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth

1. CALDWELL SH., CRESPO DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. 2004; 40(4):578-84.Search in Google Scholar

2. LONARDO A., BYRNE C., CALDWELL S., CORTEZ-PINTO H., TARGHER G. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 1388-1389.10.1002/hep.28584Open DOI Search in Google Scholar

3. FAN JG., SAIBARA T., CHITTURI S., KIM BI., SUNG JJ., CHUTAPUTTI A. What are the risk factors and settings for nonalcoholic fatty liver disease in Asia–Pacific? J Gastroenterol Hepatol. 2007; 22(6):794-800.10.1111/j.1440-1746.2007.04952.xSearch in Google Scholar

4. OGDEN CL., CARROLL MD., CURTIN LR., LAMB MM., FLEGAL KM. Prevalence of high body mass index in US children and adolescents, 2007-2008. JAMA. 2010; 303(3):242-9.10.1001/jama.2009.2012Search in Google Scholar

5. GAGGINI M., MORELLI M., BUZZIGOLI E., DEFRONZO RA., BUGIANESI E., GASTALDELLI A. Non-alcoholic fatty liver disease (NAFLD) and its connection with insulin resistance, dyslipidemia, atherosclerosis and coronary heart disease. Nutrients. 2013; 5(5):1544-60.10.3390/nu5051544Search in Google Scholar

6. AL-BUSAFI SA., BHAT M., WONG P., GHALI P., DESCHENES M. Antioxidant therapy in nonalcoholic steatohepatitis. Hepat Res Treat. 2012; 22: 947575.10.1155/2012/947575Search in Google Scholar

7. VIGANÒ M., VERGANI A., TROMBINI P., POZZI M., PALEARI F., PIPERNO A. Insulin resistance influences iron metabolism and hepatic steatosis in type II diabetes. Gastroenterology. 2000; 118(5):986-7.10.1016/S0016-5085(00)70193-4Open DOI Search in Google Scholar

8. COHEN B., NOVICK D., RUBINSTEIN M. Modulation of insulin activities by leptin. Science. 1996; 274(5290):1185.10.1126/science.274.5290.11858895466Search in Google Scholar

9. PAPPO I., BERCOVIER H., BERRY E., GALLILLY R., FEIGIN E., FREUND HR. Antitumor necrosis factor antibodies reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat. J Parenter Enteral Nutr. 1995; 19(1):80-2.10.1177/0148607195019001807658606Search in Google Scholar

10. KIRSCH R., CLARKSON V., VERDONK RC., MARAIS AD., SHEPHARD EG., RYFFEL B., et al. Rodent nutritional model of steatohepatitis: effects of endotoxin (lipopolysaccharide) and tumor necrosis factor alpha deficiency. J Gastroenterol Hepatol. 2006; 21(1):174-82.10.1111/j.1440-1746.2005.04220.x16706830Search in Google Scholar

11. BOND JR JH., LEVITT MD. Use of pulmonary hydrogen (H2) measurements to quantitate carbohydrate absorption: study of partially gastrectomized patients. J Clin Invest. 1972; 51(5):1219.10.1172/JCI1069162922535020434Open DOI Search in Google Scholar

12. SABATÉ J-M., JOUËT P., HARNOIS F., MECHLER C., MSIKA S., GROSSIN M., et al. High prevalence of small intestinal bacterial overgrowth in patients with morbid obesity: a contributor to severe hepatic steatosis. Obes Surg. 2008; 18(4):371-7.10.1007/s11695-007-9398-2Open DOI Search in Google Scholar

13. CORAZZA GR., STROCCHI A., GASBARRINI G. Fasting breath hydrogen in celiac disease. Gastroenterology. 1987; 93(1):53-8.10.1016/0016-5085(87)90313-1Search in Google Scholar

14. Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Final report. Circulation. 2002; 106:3143-3421.10.1161/circ.106.25.3143Search in Google Scholar

15. WIGG A., ROBERTS-THOMSON I., DYMOCK R., MCCARTHY P., GROSE R., CUMMINS A. The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis. Gut. 2001; 48(2):206-11.10.1136/gut.48.2.206172821511156641Open DOI Search in Google Scholar

16. SHANAB AA., SCULLY P., CROSBIE O., BUCKLEY M., O’MAHONY L., SHANAHAN F., et al. Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci. 2011; 56(5):1524-34.10.1007/s10620-010-1447-321046243Search in Google Scholar

17. RUIZ AG., CASAFONT F., CRESPO J., CAYÓN A., MAYORGA M., ESTEBANEZ A., et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg. 2007; 17(10):1374-80.10.1007/s11695-007-9243-718000721Search in Google Scholar

18. BELLOT P., FRANCÉS R., SUCH J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int. 2013; 33(1):31-9.10.1111/liv.1202123121656Search in Google Scholar

19. WIEST R., LAWSON M., GEUKING M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014; 60(1):197-209.10.1016/j.jhep.2013.07.04423993913Search in Google Scholar

20. GUPTA A., DHIMAN RK., KUMARI S., RANA S., AGARWAL R., DUSEJA A., et al. Role of small intestinal bacterial overgrowth and delayed gastrointestinal transit time in cirrhotic patients with minimal hepatic encephalopathy. J Hepatol. 2010; 53(5):849-55.10.1016/j.jhep.2010.05.01720675008Open DOI Search in Google Scholar

21. MIELE L., VALENZA V., LA TORRE G., MONTALTO M., CAMMAROTA G., RICCI R., et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009; 49(6):1877-87.10.1002/hep.2284819291785Search in Google Scholar

22. PARNELL JA., RAMAN M., RIOUX KP., REIMER RA. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int. 2012; 32(5):701-11.10.1111/j.1478-3231.2011.02730.x22221818Open DOI Search in Google Scholar

23. XU R-Y., WAN Y-P., FANG Q-Y., LU W., CAI W. Supplementation with probiotics modifies gut flora and attenuates liver fat accumulation in rat nonalcoholic fatty liver disease model. J Clin Biochem Nutr. 2011; 50(1):72-7.10.3164/jcbn.11-38324618622247604Search in Google Scholar

24. PARLESAK A., KLEIN B., SCHECHER K., BODE JC., BODE C. Prevalence of small bowel bacterial overgrowth and its association with nutrition intake in nonhospitalized older adults. J Am Geriatr Soc. 2003; 51(6):768-73.10.1046/j.1365-2389.2003.51259.x12757562Open DOI Search in Google Scholar

25. ALKHOURI N., CIKACH F., ENG K., MOSES J., PATEL N., YAN C., et al. Analysis of breath volatile organic compounds as a noninvasive tool to diagnose nonalcoholic fatty liver disease in children. Eur J Gastroenterol Hepatol. 2014; 26:82-7.10.1097/MEG.0b013e328365066924284369Search in Google Scholar

eISSN:: 2501-062X
Language:: English

Publication timeframe:: 4 times per year
Journal Subjects:: Medicine, Clinical Medicine, Internal Medicine, other, Cardiology, Gastroenterology, Rheumatology

Journal RSS Feed

Liver disease symptoms in non-alcoholic fatty liver disease and small intestinal bacterial overgrowth

Published Online: May 17, 2018

Page range: 85 - 89

Received: Aug 08, 2017

DOI: https://doi.org/10.1515/rjim-2017-0042

KeywordsNon-alcoholic fatty liver disease, Small intestinal bacterial overgrowth, Breath tests, Abdominal pain

© 2018 Rahmatollah Rafiei et al., published by De Gruyter Open

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Keywords
Non-alcoholic fatty liver disease, Small intestinal bacterial overgrowth, Breath tests, Abdominal pain